Cuál es el precio por D. Western Therapeutics Institute, Inc. (4576)

Precio por D. Western Therapeutics Institute, Inc. (4576) es de$0.5676202

Cuál es la capitalización de mercado por D. Western Therapeutics Institute, Inc. (4576)

Capitalización de mercado por D. Western Therapeutics Institute, Inc. (4576) es $32.62M

D. Western Therapeutics Institute, Inc. (4576) Desdoblamientos de Acciones

D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed for glaucoma and ocular hypertension, as well as DW-1001, another medication for eye conditions. It also provides DWR-2206, a regenerative cell-based product targeting bullous keratopathy, and DW-1002, an ophthalmic surgical aid used for staining membranes like ILM, ALC, ERM, and PVR during cataract operations. In its development pipeline, the company is advancing DW-5LBT, a lidocaine patch designed to alleviate neuropathic pain post-shingles. Additionally, K-321 is progressing through Phase III clinical trials for Fuch endothelial corneal dystrophy, and H-1337, a multi-kinase inhibitor, has commenced Phase IIb trials for glaucoma and ocular hypertension treatment. The firm was established in 1999 and operates from its headquarters in Nagoya, Japan.